AddedRisk Factors
In the ordinary course of our business, we are exposed to lawsuits, claims, proceedings and government investigations that could preclude or delay the commercialization of our products or disrupt our business
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedRisk Factors
State has appealed that injunction, and such legislation still creates a risk of significant potential exposure for settling patent litigations and, in turn, makes it more difficult to settle in the first place, which could have a material adverse effect on our business.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedRisk Factors
We are subject to changes in governmental, investor and societal responses to climate change and sustainability-related issues, which may result in scrutiny or adverse impacts on our business.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedRisk Factors
Recent changes to investor and governmental approaches to climate change and sustainability-related issues have led to evolving and sometimes conflicting expectations and standards. From time to time, we announce certain initiatives, including goals or commitments, regarding our sustainability focus areas, which include environmental matters, sustainable procurement, health equity and access to medicines, compliance and integrity and I&D. We could be criticized for the scope of such initiatives or goals or commitments, or perceived as not
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RemovedRisk Factors
We also expect to continue to experience significant adverse challenges in the U.S. generics market deriving from limitations on our ability to influence generic medicine pricing in the long term and a decrease in value from future launches and growth. If we experience further difficulty in this market, this may continue to adversely affect our revenues and profits from our United States business segment or cause us to recognize one or more goodwill impairments relating to this reporting unit.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our innovative medicines face intense competition from companies that have greater resources and capabilities and we must make significant investments in our pipeline of innovative medicines to address such competition, which may not achieve expected results.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
Furthermore, the development of innovative medicines involves lengthier and more complex processes and greater expertise and resources than those used in the development of generic medicines. For example, the time from discovery to commercial launch of an innovative medicine can be 15 years or more and involves multiple
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
The development and commercialization process, particularly with respect to innovative medicines and biosimilar medicines, as well as complex generic medicines that we increasingly focus on, is both time-
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, and the governmental and societal responses thereto, could adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
Widespread outbreaks of disease or other public health crises and responses thereto have in the past and may in the future negatively impact the global economy, disrupt global supply chains and create significant volatility and disruption of financial markets. For example, during the COVID-19 pandemic, we experienced disruptions in countries and regions in which we manufacture our products and conduct our clinical trials, as well as changes in customer stocking and purchasing patterns. In response to the COVID-19 pandemic, we temporarily closed certain of our facilities and faced other protectionist measures and restrictions imposed by government, which caused certain delays and disruptions in our materials, supply, and which also resulted in delays in our clinical trials due to slowdowns in recruitment for studies and suspended regulatory inspections, delays in regulatory approvals of new products due to reduced capacity or re-prioritization of regulatory agencies and delays in pre-commercial launch activities. The new working environment that emerged as a result of the COVID-19 pandemic, with many employees working remotely, also increased the exposure of many companies, including us, to cyber-attacks and data security breaches. Future outbreaks of disease, including a resurgence of COVID-19, and any government response thereto, could have a material adverse impact on the global economy, our supply chain, our business operations, and our financial performance.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have taken precautionary measures, and may take additional measures, intended to minimize the risks of future potential public health crises to our employees and operations.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
pharmaceutical products. We cannot guarantee that, following such efficiency measures, our business will be more efficient or effective.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
A significant portion of our costs is comprised of raw materials for our products as well as energy, transportation and labor costs for our manufacturing and operations. We have experienced increases in labor and other operational costs, partly due to macroeconomic pressures. While we seek to pass along such increased costs to our customers, there is no assurance that we will be able to successfully and promptly increase our pricing to offset such increased costs in the future. Our ability to increase our pricing may be limited or delayed by regulatory restrictions and we may only be able to increase our pricing to the extent our competitors also increase their prices, as any increase in our pricing exceeding that of our competitors could negatively impact our competitive position. Any failure to effectively and timely pass along our increased costs to our customers may adversely impact our results of operations and financial condition.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
regulations could result in fines, criminal sanctions against us, our officers or our employees, implementation of compliance programs and prohibitions on the conduct of our business. Any such violation could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to attract and retain employees, our business, our financial condition and our results of operations.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
other government purchasers, or other regulatory changes impacting reimbursement or competitive dynamics in multisource markets.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
apply to broader segments of their populations that are not Medicaid-eligible. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a reduction in demand for our products.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RewordedRisk Factors
For example, a number of jurisdictions have passed or proposed mandatory due diligence requirements in relation to forced labor and human rights matters across corporate groups as well as entity levels and supply chains, including In the EU’s European Union, these include the Directive (EU) 2024/1760 on corporate sustainability due diligence and diligence, Regulation (EU) 2023/1115 on the making available in the EU and the export from the EU of certain commodities and products associated with deforestation and forest degradation. degradation and Regulation (EU) 2024/3015 on prohibiting products made with forced labor on the EU market.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, a number of jurisdictions have passed or proposed mandatory due diligence requirements in relation to forced labor and human rights matters across corporate groups as well as entity levels and supply chains, including the EU’s Directive (EU) 2024/1760 on corporate sustainability due diligence some of which have been subject to simplification and Regulation (EU) 2023/1115 on the making available in the EU and the export from the EU of certain commodities and products associated with deforestation and forest degradation. postponement.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
The state of war declared in Israel in October 2023, and the ongoing Ongoing military activity in the region, Middle East may result in disruption to our operations and facilities, such as our manufacturing and R&D facilities located in Israel, and impact our employees, some of which are military reservists being called to active military duty, and impact the economic, social and political stability of Israel.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, Although to date our business has not been materially impacted by such geopolitical conflicts, the duration, severity and global implications (including potential inflation and devaluation consequences) of these and other geopolitical conflicts that may arise in the future, cannot be predicted at this time and could in the future have an a material and adverse effect on our business, exchange rate exposure, supply chain, operational costs and commercial presence in these markets.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, we may not be successful in our efforts from time to time seek to obtain additional patent protection for our innovative medicines through the development and commercialization of covering proprietary product improvements and and/or new and enhanced dosage forms. forms, but there are no guarantees those efforts will succeed.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
Certain of the regions in which we operate may be more susceptible to political and economic instability, such as the state of war declared in Israel in October 2023 and the ongoing military activity in the region, as well as the conflict between Russia and Ukraine, Ukraine and in the Middle East, that could result in a loss of sales in such regions.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
Following an inspection, an agency inspection or other inquiry by or interaction with the regulator, regulatory agencies have in the past and may in the future issue a notice listing conditions that are believed to violate cGMP or other laboratory, clinical, or manufacturing regulations, or take other regulatory action, including issuing a warning letter for violations of “regulatory significance” that may result in enforcement action actions if not promptly and adequately corrected.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are currently subject to several governmental and civil proceedings and (including civil litigations brought by governmental agencies and/or private plaintiffs) relating to our pricing pricing, marketing, and research and development and manufacturing practices, employment matters, intellectual property, product liability, competition matters, opioids, securities disclosures, financial reporting and accounting practices, corporate governance governance, contractual relationships with third parties (e.g. customers and suppliers), and environmental matters.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any workforce Workforce reductions, such as the reduction as part of the Teva Transformation programs announced in May 2025, and site consolidation have in the past and may in the future result in the loss of numerous long-term employees, the loss of institutional knowledge and expertise, the reallocation of certain job responsibilities, the disruption of business continuity and legal claims from affected employees, all of which could negatively affect operational efficiencies and our ability to achieve growth and profitability through the development and sale of new pharmaceutical products.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, procedures including cGMPs, problems with or shortages of raw materials, widespread outbreaks of disease or other public health crises, natural disasters, extreme weather events such as floods, heatwaves, blizzards, hurricanes, wildfires, the rise of sea level, and water stress, and other environmental factors. factors, which could have a material adverse impact on our operations and financial condition.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
The consequences of climate change, such as extreme weather and water scarcity, could pose risks to our facilities and disruption of our activities. activities, and any failure to respond to risks regarding climate change may have a material adverse effect on our business, financial condition, results of operations and reputation.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any data breach may subject us to civil fines and penalties, or regulatory orders, fines or sanctions such as under the EU GDPR or EU NIS2, or equivalent under relevant national laws, the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended, and other relevant state and federal privacy laws in the United States, including the California Consumer Privacy Act (“CCPA”) and other laws and regulations including across our International Markets.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Additionally, pharmaceutical pricing reforms in the United States have also been introduced through the enactment of the Inflation Reduction Act of 2022 (the “IRA”), which could lead has led to greater pricing pressures on our products.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Cybersecurity attacks may have become increasingly complex as they are enhanced or facilitated by the emergence of new technologies such as artificial intelligence (“AI”) that are used to identify and target new vulnerabilities in our information technology systems or those of our customers, third-party vendors and other business partners.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we are unable to complete our planned divestitures in a timely and cost-effective manner, or if we do not realize the anticipated cost savings or other benefits of such transactions, our prospects and opportunities for growth may be negatively materially adversely impacted.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The process of obtaining regulatory approvals to market a drug or medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, we continued to execute on the four key pillars of our “Pivot to Growth” strategy, announced in May 2023. As part of this strategy, in 2025, we entered the strategy’s “Accelerate Growth” phase, during which we focus on growing our innovative portfolio, aligning capital allocation to invest in activities we expect to have the highest value, and modernizing our organization and operations to drive both efficiency and cost savings. For additional information on our Pivot to Growth strategy, see “Item 1—Business—Pivot to Growth Strategy.”
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
The pharmaceutical industry has also experienced disruptions in global supply chains, including our own supply chain, due to geopolitical tensions and other factors. In some cases, such disruptions have resulted in and may continue to result in delays in our production and distribution processes, impacting product availability and our ability to timely respond to consumer demand. We have taken measures and are continually considering various initiatives, including, enhanced inventory management, alternative sourcing strategies, and backup production plans for key products, to allow us to partially mitigate and offset the impact of these factors.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
Cash flow generated from operating activities in 2025 was $1,649 million, compared to $1,247 million in 2024. The increase in 2025 resulted mainly from development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A), partially offset by higher legal settlement payments. Net changes in working capital items were neutral.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
To align with our Pivot to Growth strategy, commencing January 1, 2026, Anda will no longer be reported under our United States segment. This shift will allow the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda will be reported as part of the Company’s Other Activities. We will align our internal financial and segment reporting in coordination with this shift effective January 1, 2026.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
Generic Name Brand Name Total U.S. Annual Branded Market (U.S. $ in millions (IQVIA))* Rimegepant Orally Disintegrating Tablets, 75mg Nurtec ODT® $4,100 Prucalopride Tablets, 1 mg and 2 mg Motegrity® $173 Elagolix Tablets, 150 mg and 200 mg Orilissa® $150 Azacitidine Tablets, 200 mg and 300 mg Onureg® $141 Octreotide Delayed-release Capsules, 20 mg Mycapssa® No Data Nintedanib Capsules, 100 mg and 150 mg Ofev® $3,280 Macitentan Tablets Opsumit® $1,181 Elagolix, Estradiol and Norethindrone Acetate Capsules, 300 mg / 1 mg / 0.5 mg; Elagolix Capsules, 300 mg Oriahnn® $11
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
On March 31, 2025, we divested our Teva-Takeda business venture in Japan, which included generic products and legacy products. Since the establishment of the business venture and until the completion of its sale, Teva held 51% of the outstanding common stock of the business venture. On March 31, 2025, we deconsolidated the business venture from our financial statements. For additional information, see notes 2 and 22 to our consolidated financial statements.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
Net Income (Loss) Attributable to redeemable and non-redeemable non-controlling interests
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
In January 2025, we repaid $426 million of the 6% senior notes at maturity and $427 million of the 7.13% senior notes at maturity.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
In February 2026, we repaid $23 million of the 0.25% convertible senior debentures at maturity.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
Cash flow generated from operating activities in 2025 was $1,649 million, compared to $1,247 million in 2024. The increase in 2025 resulted mainly from development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A), partially offset by higher legal settlement payments. Net changes in working capital items were neutral.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
AddedMD&A
(4) In 2025, Teva recorded $225 million of restructuring expenses primarily related to optimization activities in connection with Teva’s Transformation programs related to Teva’s global organization and operations, mainly through headcount reduction.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RemovedMD&A
We are a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery and expanded development of modern medicine.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
In 2024, we continued to execute on the four key pillars of our “Pivot to Growth” strategy, which we announced in May 2023.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
On the first pillar, delivering on our growth engines, we continued to show strong performance of our key innovative products, mainly AUSTEDO, AJOVY, and UZEDY, as well as on our late-stage pipeline of biosimilars, with the launches of SIMLANDI® (adalimumab-ryvk) injection and the expected launch of SELARSDI (ustekinumab-aekn) injection, and the progress we made on our proposed biosimilars to Prolia®, Simponi® and Simponi Aria® which were submitted for regulatory review in the U.S. and the EU;
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
On the second pillar, stepping up innovation through delivering on our late-stage innovative pipeline, we have been accelerating the development of certain key pipeline assets, including the recent positive Phase 2b results for duvakitug (anti-TL1A), and expect a number of milestones and data points for olanzapine LAI and DARI (Dual-action Asthma Rescue Inhaler, ICS/SABA) in the near future;
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
On the third pillar, sustaining our generic medicines powerhouse with a global commercial footprint, focused portfolio, pipeline and manufacturing footprint, we continued to optimize our generics business and build a strong pipeline of biosimilars, with several successful launches of high-value complex generics in 2024; and
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
Lastly, on our fourth pillar, focusing our business by optimizing our portfolio and global manufacturing footprint. This will enable strategic capital deployment, to accelerate our growth engines and reorganize certain of our business units to a more optimal structure. We continued our efforts on capital allocation and disciplined cost management by focusing on debt repayment, and optimizing our working capital management.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
Cash flow generated from operating activities in 2024 was $1,247 million, compared to $1,368 million in 2023. The decrease in 2024 resulted mainly due to an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, a negative impact from accounts payables, the classification of payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid®) as cash flow used in operating activities, and higher tax payments, partially offset by higher profit from AUSTEDO and from the sale of certain product rights, lower inventory levels, and a positive impact from accounts receivables.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
As part of a recent shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing January 1, 2024, Canada is reported as part of our International Markets segment. Prior period amounts were recast to reflect this change. See note 19 to our consolidated financial statements.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira®, for the treatment of adult rheumatoid arthritis,
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On May 21, 2024, Alvotech and Teva announced the availability of SIMLANDI in the U.S.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RemovedMD&A
On June 24, 2024, Teva announced the launch of liraglutide injection 1.8mg (an authorized generic of Victoza®) in the United States. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Read it in 10-K Feb 5, 2025 at sec.govopen_in_new
RewordedMD&A
(1) Adjustments for legal settlements and loss contingencies in 2024 2025 were mainly related to legal expenses of $357 million recorded in connection with a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision of $278 $220 million for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments payments), an update of $56 million related to the provision recorded for the carvedilol patent litigation, an update of $55 million related to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the settlement agreement with United States in the city generic drug antitrust litigation, as well as a provision of Baltimore). $35 million recorded for the antitrust litigation related to QVAR.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
Amortization of purchased intangible assets 581 588 616 Legal settlements and loss contingencies(1) 473 761 1,043 Goodwill impairment(2) — 1,280 700 Impairment of long-lived assets(3) 1,029 1,275 378 Restructuring costs costs(4) 225 74 111 Equity compensation 157 123 121 Contingent consideration(4) consideration(5) 54 303 548 Loss (Gain) on sale of business 22 (15) (3) Accelerated depreciation 21 13 80 Financial expenses 69 49 66 Items attributable to non-controlling interests(3) 2 (339) (92) Other non-GAAP items(5) items(6) 186 229 335 Corresponding tax effects and unusual tax items(6) items(7) (819) 157 (446) Non-GAAP net income attributable to Teva ($) ($) 3,411 2,860 2,898 Non-GAAP tax rate(7) rate(8) 15.8% 15.3% 13.0% GAAP diluted earnings (loss) per share attributable to Teva ($) ($) 1.21 (1.45) (0.50) EPS difference(8) difference(9) 1.72 3.94 3.06 Non-GAAP diluted EPS attributable to Teva(8) Teva(9) ($) ($) 2.93 2.49 2.56 Non-GAAP average number of shares (in millions)(8) millions)(9) 1,163 1,150 1,131
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
This increase decrease was mainly due to lower proceeds from the sale of certain product rights, price increases largely as a result of higher costs due to inflationary pressure, a favorable mix of products sold, rights and a positive negative hedging impact, partially offset by regulatory price reductions increases due to inflationary pressure in certain markets and generic competition to off-patented products in Japan. a favorable mix of products.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
This increase in gross profit margin was mainly due to a favorable mix of products, primarily driven by higher revenues from AUSTEDO AUSTEDO, and lenalidomide capsules (the generic version development milestone payments received in connection with the initiation of Revlimid®), and Phase 3 studies for duvakitug (anti-TL1A), partially offset by lower proceeds from the sale of certain product rights, partially offset by an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset. rights.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
The following main currencies relevant to our operations increased in value against the U.S. dollar: the Polish zloty Russian ruble by 11%, the Swedish krona by 8%, the new Israeli shekel by 7%, the Swiss franc by 6%, the Polish złoty by 6%, the euro by 4%, the Bulgarian lev by 4% and the British pound by 3% and the Swiss franc by 2%. 3%.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
This decrease increase was mainly due to an upfront payment the development milestone payments received in 2023 related to connection with the collaboration on our initiation of Phase 3 studies for duvakitug (anti-TL1A) asset, partially offset by (anti-TL1A), and a favorable mix of products primarily driven by higher revenues from AUSTEDO and lenalidomide capsules (the generic version of Revlimid®). AUSTEDO.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
API sales to third parties in 2024 2025 were $553 million, reflecting an increase $526 million a decrease of 3% 5% in both U.S. dollars and local currency terms compared to 2023, following a reallocation of an immaterial business within our other activities, in line with our intention 2024, mainly due to divest our API business. lower demand.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
During 2024, 2025, the following main currencies relevant to our operations decreased in value against the U.S. dollar (each on an annual average compared to annual average basis): the Argentinian peso by 68%, 26%, the Turkish lira by 28%, 17%, the Chilean Mexican peso by 11%, 5%, the Brazilian real by 4%, Indian rupee by 4% and the Ukraine hryvna by 8%, the Russian ruble by 8%, the Brazilian real by 7% and the Japanese yen by 7%. 4%.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
(6) (7) Adjustments for corresponding tax effects and unusual tax items in 2024 2025 include a an income tax item in an amount of $495 $246 million related to a valuation allowance release in the settlement agreement with the ITA to settle certain litigation with respect to taxes payable for the Company’s taxable years 2008 through 2020. U.S.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
In local currency terms, revenues increased decreased by 4%, 5%, mainly due to higher the year-over-year impact from the sale of certain product rights, lower revenues from generic and OTC products products, as well as COPAXONE, partially offset by higher revenues from AJOVY, partially offset by lower revenues from COPAXONE, respiratory products and other products. AJOVY.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
Our higher R&D expenses, net in 2024, 2025, compared to 2023, 2024, were mainly due to an increase in immunology and in immuno-oncology, our late-stage innovative pipeline as well as in neuroscience (mainly neuropsychiatry), and our biosimilars pipeline, neurodegeneration), partially offset by a decline in various the non-recurrence of milestone payments related to certain biosimilar projects, and lower expenses related to generics projects.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
RewordedMD&A
In local currency terms, revenues increased decreased by 6%, 2%, mainly due to lower volumes and price increases reductions as a result of market conditions such as inflationary pressures in certain markets, as well as dynamics, and lower sales of seasonal OTC products, partially offset by higher revenues from recently launched products.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new
Quiet changesMD&A
Profit of our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and any other loss expenses (income) related to this segment.
Read it in 10-K Feb 3, 2026 at sec.govopen_in_new